Q-omics provides the consensus-scored ADIG profile across patient tissues and cancer cell-line models. ADIG expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ADIG is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ADIG RNA expression shows 7,030 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, THCA, and STAD as cancer lineages where ADIG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADIG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADIG survival associations across molecular data types. ADIG RNA expression shows survival associations in the most cancer types (9), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADIG RNA expression–survival associations across cancer types. High ADIG expression shows unfavorable associations in DLBC, LGG, KIRC and THYM, but favorable associations in CESC and SCLC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ADIG RNA expression.
This table summarizes ADIG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ADIG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADIG shows lower tumor expression in THCA, KICH, KIRC, KIRP and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher ADIG RNA expression in normal versus tumor tissue (log2 FC = −2.722, t-test p < 0.001).
This table shows molecular features associated with ADIG in patient tissues and cancer cell lines. In patient samples, ADIG shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ADIG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LIVER.
